Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer - PubMed (original) (raw)
Clinical Trial
Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer
J Nemunaitis et al. Cancer Gene Ther. 2006 Jun.
Abstract
Tumor vaccines composed of autologous tumor cells genetically modified to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF) (GVAX) have demonstrated clinical activity in advanced-stage non-small-cell lung cancer (NSCLC). In an effort to remove the requirement for genetic transduction of individual tumors, we developed a 'bystander' GVAX platform composed of autologous tumor cells mixed with an allogeneic GM-CSF-secreting cell line. We conducted a phase I/II trial of this vaccine (3-12 biweekly vaccinations) in advanced-stage NSCLC. Tumors were harvested from 86 patients, tumor cell processing was successful in 76, and 49 proceeded to vaccination. The most common toxicity was local vaccine injection site reactions. Serum GM-CSF pharmacokinetics were consistent with secretion of GM-CSF from vaccine cells for up to 4 days with associated transient leukocytosis confirming the bioactivity of vaccine-secreted GM-CSF. Evidence of vaccine-induced immune activation was demonstrated; however, objective tumor responses were not seen. Compared with autologous GVAX vaccines prepared by transduction of individual tumors with an adenoviral GM-CSF vector, vaccine GM-CSF secretion was approximately 25-fold higher with the bystander GVAX vaccine used in this trial. However, the frequency of vaccine site reactions, tumor response, time to disease progression, and survival were all less favorable in the current study.
Similar articles
- Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer.
Nemunaitis J, Sterman D, Jablons D, Smith JW 2nd, Fox B, Maples P, Hamilton S, Borellini F, Lin A, Morali S, Hege K. Nemunaitis J, et al. J Natl Cancer Inst. 2004 Feb 18;96(4):326-31. doi: 10.1093/jnci/djh028. J Natl Cancer Inst. 2004. PMID: 14970281 Clinical Trial. - Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response.
Rüttinger D, van den Engel NK, Winter H, Schlemmer M, Pohla H, Grützner S, Wagner B, Schendel DJ, Fox BA, Jauch KW, Hatz RA. Rüttinger D, et al. J Transl Med. 2007 Sep 14;5:43. doi: 10.1186/1479-5876-5-43. J Transl Med. 2007. PMID: 17868452 Free PMC article. Clinical Trial. - Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.
Nelson WG, Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Kim M, Weber CE, Baccala AA, Goeman MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF. Nelson WG, et al. Cancer Chemother Pharmacol. 2000;46 Suppl:S67-72. doi: 10.1007/pl00014053. Cancer Chemother Pharmacol. 2000. PMID: 10950151 Clinical Trial. - Vaccines in cancer: GVAX, a GM-CSF gene vaccine.
Nemunaitis J. Nemunaitis J. Expert Rev Vaccines. 2005 Jun;4(3):259-74. doi: 10.1586/14760584.4.3.259. Expert Rev Vaccines. 2005. PMID: 16026242 Review. - Granulocyte-macrophage colony-stimulating factor gene-transfected autologous tumor cell vaccine: focus[correction to fcous] on non-small-cell lung cancer.
Nemunaitis J, Nemunaitis J. Nemunaitis J, et al. Clin Lung Cancer. 2003 Nov;5(3):148-57. doi: 10.3816/clc.2003.n.027. Clin Lung Cancer. 2003. PMID: 14667270 Review.
Cited by
- Cracking the Codes behind Cancer Cells' Immune Evasion.
Mundhara N, Sadhukhan P. Mundhara N, et al. Int J Mol Sci. 2024 Aug 15;25(16):8899. doi: 10.3390/ijms25168899. Int J Mol Sci. 2024. PMID: 39201585 Free PMC article. Review. - Neoantigen Identification and Dendritic Cell-Based Vaccines for Lung Cancer Immunotherapy.
Kumari K, Singh A, Chaudhary A, Singh RK, Shanker A, Kumar V, Haque R. Kumari K, et al. Vaccines (Basel). 2024 May 5;12(5):498. doi: 10.3390/vaccines12050498. Vaccines (Basel). 2024. PMID: 38793749 Free PMC article. Review. - Engineering a versatile and retrievable cell macroencapsulation device for the delivery of therapeutic proteins.
Grogg J, Vernet R, Charrier E, Urwyler M, Von Rohr O, Saingier V, Courtout F, Lathuiliere A, Gaudenzio N, Engel A, Mach N. Grogg J, et al. iScience. 2023 Jul 13;26(8):107372. doi: 10.1016/j.isci.2023.107372. eCollection 2023 Aug 18. iScience. 2023. PMID: 37539029 Free PMC article. - Vaccinating against cancer: getting to prime time.
Chang R, Gulley JL, Fong L. Chang R, et al. J Immunother Cancer. 2023 Jun;11(6):e006628. doi: 10.1136/jitc-2022-006628. J Immunother Cancer. 2023. PMID: 37286302 Free PMC article. Review. - Vaccine Therapy in Non-Small Cell Lung Cancer.
García-Pardo M, Gorria T, Malenica I, Corgnac S, Teixidó C, Mezquita L. García-Pardo M, et al. Vaccines (Basel). 2022 May 9;10(5):740. doi: 10.3390/vaccines10050740. Vaccines (Basel). 2022. PMID: 35632496 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical